Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Shiv K. Singh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5725-4058; OpenAlex author ID A5018404918. Sources: OpenAlex.

Their work

Papers
29 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
97
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 3 papers · 2024: 3 papers · 2025: 2 papers · 2026: 3 papers

Papers 29

  1. Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2026.117649↗
  2. Tumor-intrinsic dichotomy shapes cellular heterogeneity in pancreatic cancer. First author DOI 10.1016/j.trecan.2025.11.003↗
  3. GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair. Co-author DOI 10.1136/gutjnl-2025-336227↗
  4. Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Last author DOI 10.1038/s41467-024-55330-7↗
  5. TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. Last author DOI 10.1126/sciadv.adu2339↗
  6. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing. Co-author DOI 10.1016/j.neo.2024.101002↗
  7. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  8. Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2024.1323198↗
  9. RBFOX2: a key factor in suppressing PDAC metastasis through regulation of alternative splicing events. First author DOI 10.1038/s41392-023-01585-3↗
  10. Neutrophil-derived complement factor P induces cytotoxicity in basal-like cells via caspase 3/7 activation in pancreatic cancer Last author DOI 10.1101/2023.10.28.564512↗
  11. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Co-author DOI 10.1136/gutjnl-2022-327855↗
  12. Mechanisms of PDAC subtype heterogeneity and therapy response. Last author DOI 10.1016/j.trecan.2022.08.005↗
  13. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. Last author DOI 10.1172/jci.insight.154475↗
  14. TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. Co-author DOI 10.3390/cancers14143451↗
  15. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Last author DOI 10.1038/s43018-021-00258-w↗
  16. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  17. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. Co-author DOI 10.3389/fonc.2021.642603↗
  18. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer. Co-author DOI 10.3390/cells10123463↗
  19. Microenvironmental Determinants of Pancreatic Cancer. Co-author DOI 10.1152/physrev.00042.2019↗
  20. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Co-author DOI 10.1158/0008-5472.can-20-0672↗
  21. A tangled tale of molecular subtypes in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-318086↗
  22. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. Co-author DOI 10.3390/cells8060563↗
  23. A Recombinant Fragment of Human Surfactant Protein D induces Apoptosis in Pancreatic Cancer Cell Lines via Fas-Mediated Pathway. Co-author DOI 10.3389/fimmu.2018.01126↗
  24. Human Surfactant Protein D Suppresses Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells by Downregulating TGF-β. Co-author DOI 10.3389/fimmu.2018.01844↗
  25. GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. Co-author DOI 10.1158/1535-7163.mct-15-0309↗
  26. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. Co-author DOI 10.15252/embj.201489574↗
  27. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Co-author DOI 10.1158/2159-8290.cd-13-0593↗
  28. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Co-author DOI 10.1053/j.gastro.2011.11.001↗
  29. Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. Co-author DOI 10.1074/jbc.m110.197533↗

Closest collaborators

The 25 strongest of 97 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Volker Ellenrieder · 19 shared papers, 2011–2026 · strength 2.12
  2. Elisabeth Heßmann · 16 shared papers, 2014–2026 · strength 1.92
  3. Lukas Klein · 9 shared papers, 2021–2026 · strength 1.53
  4. Albrecht Neeße · 13 shared papers, 2014–2024 · strength 1.39
  5. Laura Urbach · 6 shared papers, 2020–2025 · strength 1.12
  6. Uday Kishore · 7 shared papers, 2018–2025 · strength 1.04
  7. Rebecca Diya Samuel · 3 shared papers, 2025–2026 · strength 1.03
  8. Elisa Espinet Espinet · 5 shared papers, 2021–2025 · strength 0.71
  9. Mengyu Tu · 5 shared papers, 2021–2025 · strength 0.67
  10. Ulrich Sax · 3 shared papers, 2024–2026 · strength 0.56
  11. Steven A. Johnsen · 4 shared papers, 2020–2026 · strength 0.51
  12. Argyris Papantonis · 3 shared papers, 2021–2026 · strength 0.50
  13. Andreas Trumpp · 4 shared papers, 2021–2025 · strength 0.49
  14. Lennart Versemann · 4 shared papers, 2020–2024 · strength 0.48
  15. Thomas Mathias Gress · 7 shared papers, 2011–2023 · strength 0.47
  16. Shilpa Patil · 4 shared papers, 2019–2022 · strength 0.43
  17. Günter Schneider · 3 shared papers, 2021–2026 · strength 0.43
  18. Lena‐Christin Conradi · 2 shared papers, 2026 · strength 0.42
  19. Muhammad Umair Latif · 2 shared papers, 2025–2026 · strength 0.39
  20. Ramona Schulz‐Heddergott · 2 shared papers, 2021–2025 · strength 0.37
  21. Christoph Ammer‐Herrmenau · 2 shared papers, 2024 · strength 0.34
  22. Adi Danieli‐Mackay · 2 shared papers, 2021–2026 · strength 0.31
  23. Nelson Dusetti · 2 shared papers, 2021–2025 · strength 0.31
  24. Niklas Krebs · 2 shared papers, 2022–2025 · strength 0.30
  25. Robert G. Goetze · 2 shared papers, 2019–2024 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.